Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMEA3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $138,634
Award facts
- Contract value 100% obligated
- $138,633.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $138,633.60 by the Defense Logistics Agency on December 8, 2025, for the supply of BOTOX 200 Unit Vials. This firm fixed-price delivery order is scheduled for completion by December 30, 2025, and carries no set-aside designation, indicating the company competed for the award in unrestricted federal procurement. The contract is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy established to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare operations.
The PPV-G GEN V program, under which this delivery order was issued, represents a strategic sourcing vehicle designed to ensure reliable pharmaceutical supply chains for military healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award IDC under this program with a ceiling value of $499,999,999 and a completion date of December 31, 2036, positioning the company as a critical regional prime vendor contractor. The company's extensive product portfolio and demonstrated performance across multiple therapeutic categories, including specialty pharmaceuticals and biologics, supports its role in fulfilling the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FMEA3?
SPE2DR26FMEA3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FMEA3 worth?
The government has obligated $138,634 on SPE2DR26FMEA3.
Is contract SPE2DR26FMEA3 an order under another contract?
Yes. SPE2DR26FMEA3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEA3 competed?
The extent of competition for SPE2DR26FMEA3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award